NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/05/2022
Back to search
Official data from USPTO
AVERITAS PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
AVERITAS PHARMA
ST13
US500000088984225Class
41
Filing
88984225
Registration
6782940
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
52
Latest update
07/05/2022
Trademark type
Word
Nice classes
41
Filing date
08/24/2018
Registration date
07/05/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/05/2022
Last transaction
07/05/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2020-08-00
First use in commerce
2020-08-00
Drawing code
4
Owner type
03
Owner location
Morristown, NJ
Examiner
OH,WON TEAK
Law office
M50
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Averitas Pharma, Inc.
Representatives
Paul C. Llewellyn ARNOLD & PORTER KAYE SCHOLER LLP
Technical classification
Nice Classes
Class 41
Vienna Codes
No Vienna codes available.
Goods and services
Class 41
Conducting of training courses in the field of medicine and pharmaceuticals
Publications
History of USPTO decisions and trademark events.
52 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
07/05/2022
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
06/01/2022
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
05/31/2022
SUPC
STATEMENT OF USE PROCESSING COMPLETE
05/16/2022
DPCC
DIVISIONAL PROCESSING COMPLETE
05/16/2022
IUAF
USE AMENDMENT FILED
03/07/2022
DRRR
DIVISIONAL REQUEST RECEIVED
03/07/2022
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
03/07/2022
EISU
TEAS STATEMENT OF USE RECEIVED
03/07/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/30/2021
EX5G
SOU EXTENSION 5 GRANTED
11/29/2021
EXT5
SOU EXTENSION 5 FILED
11/18/2021
EEXT
SOU TEAS EXTENSION RECEIVED
11/18/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/30/2021
EX4G
SOU EXTENSION 4 GRANTED
04/28/2021
EXT4
SOU EXTENSION 4 FILED
04/28/2021
EEXT
SOU TEAS EXTENSION RECEIVED
04/28/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/18/2020
EX3G
SOU EXTENSION 3 GRANTED
11/16/2020
EXT3
SOU EXTENSION 3 FILED
11/16/2020
EEXT
SOU TEAS EXTENSION RECEIVED
11/16/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/29/2020
EX2G
SOU EXTENSION 2 GRANTED
05/27/2020
EXT2
SOU EXTENSION 2 FILED
05/27/2020
EEXT
SOU TEAS EXTENSION RECEIVED
05/27/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
01/15/2020
NOAC
CORRECTED NOA E-MAILED
01/15/2020
EX1G
SOU EXTENSION 1 GRANTED
01/14/2020
DPCC
DIVISIONAL PROCESSING COMPLETE
01/14/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/20/2019
INCD
ITU OFFICE ACTION ISSUED FOR DIVISIONAL REQUEST
12/10/2019
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
12/10/2019
EXT1
SOU EXTENSION 1 FILED
12/06/2019
EEXT
SOU TEAS EXTENSION RECEIVED
12/06/2019
DRRR
DIVISIONAL REQUEST RECEIVED
12/05/2019
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
12/05/2019
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
06/25/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/30/2019
PUBO
PUBLISHED FOR OPPOSITION
04/30/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/10/2019
ALIE
ASSIGNED TO LIE
03/22/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/28/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/14/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/13/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/13/2019
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
12/13/2018
GPRA
PRIORITY ACTION E-MAILED
12/13/2018
CPRA
PRIORITY ACTION WRITTEN
12/13/2018
DOCK
ASSIGNED TO EXAMINER
12/10/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/04/2018
NWAP
NEW APPLICATION ENTERED
08/28/2018
Continuous trademark protection
Get notified about every new filing that threatens AVERITAS PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.